Back HIV/AIDS

HIV / AIDS

CROI 2016: Women and African Americans with HIV Have a Higher Risk of Stroke

The risk of stroke among people living with HIV is highest among people with unsuppressed viral load, and among women and African Americans, according to findings presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.

alt

NIAID To Fund Follow-Up Study of Dapivirine Vaginal Ring for HIV Prevention

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, will support an open-label continuation study of the dapivirine vaginal ring that demonstrated modest protection against HIV infection, especially among older women, in 2 clinical trials in Africa, as reported at the recent Conference on Retroviruses and Opportunistic Infections in Boston.

alt

CROI 2016: Rapid Rise in PrEP Awareness in U.S. Gay Men, But Only 5% Have Used PrEP

Large internet surveys of American gay men show that the proportion who have heard of pre-exposure prophylaxis (PrEP) jumped from 45% in 2012 to 68% in 2015, with around half of men willing to consider using PrEP -- but that actual usage is far lower and remains concentrated in a few key urban areas where public health authorities have facilitated its uptake, according to data presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016)in Boston.

alt

CROI 2016: Combination Inhibitor BMS-986197 Demonstrates Good Anti-HIV Activity in Early Study

A long-acting bioengineered "combinectin" molecule with a triple mechanism of action demonstrated potent antiviral activity and worked against HIV that developed resistance to any of the 3 separate mechanisms in a laboratory study, and lowered viral load in humanized mice, according to research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.

alt

CROI 2016: PopART Shows Feasibility of Reaching 90-90-90 HIV Testing and Treatment Targets

Early findings from the PopART study of the impact of a test-and-treat strategy on antiretroviral treatment coverage and HIV incidence show that after one round of household-based testing, linkage to care, and offer of immediate antiretroviral therapy, 90% of adults knew their HIV status and 71% of adults diagnosed with HIV were on treatment, according to preliminary findings presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston. The primary outcome of the study -- the impact of expanded treatment coverage on HIV incidence -- is expected to be reported in mid-2018.

alt

CROI 2016: High STI Rates Among Gay Men on PrEP Supports More Frequent Monitoring

Participants taking tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP) continued to have high rates of sexually transmitted infections (STIs) in 2 U.S. PrEP demonstration projects, according to a pair of reports at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston. Semi-annual STI testing missed many cases, leading researchers to suggest that gay men on PrEP could benefit from screening every 3 months.

alt

CROI 2016: Cotrimoxazole Prophylaxis Provides No Benefit for HIV-Exposed Uninfected Children

Challenging current guidelines, prolonged use of cotrimoxazole may not be necessary for HIV-exposed but uninfected children in low-mortality, non-malarial settings with low risk for late mother-to-child transmission throug breastfeeding, Roger Shapiro told participants at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

alt